



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	324305	Gluco Metabolism
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Nutrition Care Pharmaceuticals Pty Ltd	
<b>Postal Address</b>	25-31 Keysborough Avenue, Keysborough, VIC, 3173 Australia	
<b>ARTG Start Date</b>	2/10/2019	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Gluco Metabolism

Product Type	Single Medicine Product	Effective Date	2/10/2019
--------------	-------------------------	----------------	-----------

### Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Helps convert (state food) into energy
- Maintain/support energy production
- Traditionally used in Western herbal medicine to maintain/support general health and wellbeing
- Traditionally used in Chinese medicine to maintain/support general health and wellbeing
- Maintain/support general health and wellbeing
- Traditionally used in Chinese medicine to decrease/reduce/relieve abdominal pain/discomfort
- Aid/assist/helps glucose/sugar/carbohydrate metabolism
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
- Maintain/support skin health

### Indication Requirements

- Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.
- If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.
- Label statement: If symptoms persist, talk to your health professional.
- If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Public Summary



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

Product presentation must not imply or refer to gastro oesophageal reflux disease.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet. If symptoms persist consult your healthcare practitioner (or words to that effect).

**Additional Product information**

**Pack Size/Poison information**

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

**Components**

**1 . Formulation 1**

**Dosage Form**                      Tablet, film coated

**Route of Administration**      Oral

**Visual Identification**

**Active Ingredients**

<b>alpha lipoic acid</b>	<b>50 mg</b>
<b>Biotin</b>	<b>1.33 mg</b>
<b>chromium picolinate</b>	<b>66.7 microgram</b>
Equivalent: chromium	8.3 microgram
<b>Cinnamomum cassia stem bark Extract dry concentrate</b>	<b>22.22 mg</b>
Equivalent: Cinnamomum cassia (Dry)	333.3 mg
<b>Gymnema sylvestre leaf Extract dry concentrate</b>	<b>133.33 mg</b>
Equivalent: Gymnema sylvestre (Dry)	2.67 g
<b>Momordica charantia fruit Extract dry concentrate</b>	<b>41.67 mg</b>
Equivalent: Momordica charantia (Dry)	333.36 mg
<b>Nigella sativa seed Extract dry concentrate</b>	<b>8.33 mg</b>
Equivalent: Nigella sativa (Dry)	83.3 mg
<b>Portulaca oleracea whole plant Extract dry concentrate</b>	<b>8.33 mg</b>
Equivalent: Portulaca oleracea (Dry)	83.3 mg
<b>Trigonella foenum-graecum seed Extract dry concentrate</b>	<b>40 mg</b>
Equivalent: Trigonella foenum-graecum (Dry)	500 mg

**Other Ingredients (Excipients)**

- calcium hydrogen phosphate dihydrate
- Carnauba Wax
- chlorophyllin-copper complex
- colloidal anhydrous silica
- croscarmellose sodium
- crospovidone
- ethylcellulose
- indigo carmine
- lecithin
- macrogol 3000
- magnesium stearate
- maltodextrin

Public Summary



**Australian Government**

**Department of Health**  
Therapeutic Goods Administration

microcrystalline cellulose

polyvinyl alcohol

povidone

purified talc

titanium dioxide

---

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary